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Growing Evidence for Its Beneﬁcial Role in Heart Failure*Kai C. Wollert, MDSEE PAGE 207H eart failure with preserved ejection fraction(HFpEF) is associated with debilitatingsymptoms, recurrent hospitalizations, and
a poor prognosis similar to that in heart failure with
reduced ejection fraction (HFrEF). Major clinical trials
have failed to identify speciﬁc drug therapies for
HFpEF. These disappointing results have been attrib-
uted in part to an incomplete understanding of
HFpEF pathophysiology (1).
Follistatin-like 1 (FSTL1) is a secreted glycoprotein
that was originally cloned as a transforming growth
factor b-inducible gene (2). FSTL1 shares a structural
motif, the follistatin domain, with follistatin,
follistatin-like 3, and members of the secreted protein
acidic and cysteine rich (SPARC) protein family.
Overall, FSTL1 displays a low degree of amino acid
sequence similarity with these other proteins, sug-
gesting that it has evolved distinct functions. FSTL1 is
weakly expressed in the normal myocardium but
strongly induced in mice with HFrEF after transverse
aortic constriction (3). Hypertrophied cardiac myo-
cytes have emerged as the main producers of FSTL1 in
this setting. Notably, genetic deletion of FSTL1 in
cardiomyocytes exacerbated cardiac (myocyte) hy-
pertrophy and systolic dysfunction in the HFrEF
model (3). Outside the heart, FSTL1 has been shown
to promote inﬂammation and ﬁbrosis (4,5).
Comorbidities such as arterial hypertension and
diabetes have been proposed to drive microvascular
inﬂammation, ﬁbrosis, and cardiomyocyte hypertro-
phy in HFpEF (6), disease pathways that may all be
inﬂuenced by FSTL1 (3–5). In this issue of JACC: Basic*Editorials published in JACC: Basic to Translational Science reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Basic to Translational Science or the American College of Cardiology.
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postulated that FSTL1 plays a role in HFpEF. In their
study, mice were subjected to unilateral nephrectomy
followed by intraperitoneal infusion of aldosterone
and addition of NaCl to the drinking water for 4
weeks. The animals developed arterial hypertension
with concentric left ventricular hypertrophy, inter-
stitial ﬁbrosis, and diastolic dysfunction on Doppler
echocardiography. Left ventricular ejection fraction
was preserved, and wet lung weight was (slightly)
increased, indicating that the animals had developed
HFpEF with pulmonary congestion. Considering thechallenges of using Doppler echocardiography to
assess diastolic function in mice (8), pressure-volume
loop analyses would have strengthened the data.
Genetic deletion of FSTL1 in cardiomyocytes did not
affect arterial blood pressure, but worsened cardiac
(myocyte) hypertrophy, diastolic dysfunction, and
pulmonary congestion (7). These data support the idea
that FSTL1 provides an autocrine feedback loop to
protect from maladaptive cardiac hypertrophy in
HFrEF and now also HFpEF (3,7). Notably, mice lack-
ing FSTL1 in cardiomyocytes developed enhanced
cardiac ﬁbrosis in the HFrEFmodel, but not the HFpEF
model, indicating that FSTL1 may also exert anti-
ﬁbrotic effects under speciﬁc experimental conditions
(3,7). Inﬂammatory cells and endothelial cells partici-
pate in the regulation of cardiac hypertrophy, ﬁbrosis,
and remodeling during pressure-overload (9), but the
impact of FSTL1 on these non-myocyte cell types in
HFrEF or HFpEF currently remains unknown.
To start exploring the clinical ramiﬁcations of their
study, Tanaka et al. (7) measured serum FSTL1 con-
centrations in 32 patients with HFpEF using a
commercially available immunoassay. Patients had
higher circulating FSTL1 levels (mean 167 ng/ml) than
8 apparently healthy individuals (96 ng/ml) (7).
At ﬁrst sight, this observation conﬁrms a previous
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6 Wollert
J U N E 2 0 1 6 : 2 2 2 – 3 Follistatin-Like 1 in Heart Failure
223report from the same group documenting elevated
FSTL1 levels in patients with HFrEF (10). However,
the concentrations measured in the present study
are surprisingly high (7). In a previous study, FSTL1
concentrations in 120 apparently healthy individuals
ranged from 1 to 18 ng/ml (11). Other investigators
have measured similar FSTL1 concentrations in
apparently healthy individuals (12,13). The very high
FSTL1 concentrations reported in the present study
(7), and by others (14), remain unexplained. In the
HFrEF patients, serum FSTL1 was measured by SDS-
PAGE and immunoblotting, and protein standards
were used to ascertain the appropriate size of the
FSTL1 band (10); concentrations in the HFrEF study
were reported as arbitrary units, thus precluding a
direct comparison with the HFpEF data (10). The
speciﬁcity of an immunoassay also needs to be
established, especially in a complex matrix such as
serum or plasma. For example, size-exclusion chro-
matography can be used to conﬁrm that an immu-
noassay detects a single analyte with the correct size
(w50,000 kDa in the case of human FSTL1) (11). Such
an analysis was not performed in the current report
(7), and this critical information is also not provided
by the vendor of the immunoassay.
In any case, the beneﬁcial effects of endogenous
FSTL1 in HFrEF and HFpEF models, suggest that
augmentation of FSTL1 signaling could be a thera-
peutic approach in heart failure. In fact, transgenicoverexpression of FSTL1 mitigated left ventricular
hypertrophy, ﬁbrosis, and systolic dysfunction in the
murine HFrEF model (3). Likewise, adenoviral trans-
fer of FSTL1 attenuated cardiac hypertrophy and
diastolic dysfunction in the HFpEF model (7). Trans-
lation of these ﬁndings into clinical practice may be
challenging if long-term FSTL1 gene overexpression
or protein delivery is required in patients with heart
failure. Potential extracardiac side effects also need
to be considered (4,5). Acute conditions may repre-
sent more feasible indications for FSTL1 therapies.
Indeed, capitalizing on the antiapoptotic effects of
FSTL1 in cardiac myocytes (15), a brief intracoronary
infusion of FSTL1 has been shown to reduce infarct
size in pigs with acute myocardial infarction (16). A
recent study indicated that application of FSTL1 via
an epicardial patch enhances cardiomyocyte prolif-
eration and systolic function after acute myocardial
infarction (17), further heightening interest in FSTL1
as a therapeutic agent (18). Ultimately, new therapies
may emerge from a better understanding of the
mechanisms whereby FSTL1 exerts its multifaceted
effects in acute and chronic heart diseases.
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